Announced details
DDAIF has been adopted by multiple major pharmaceutical companies
FRONTEO and 小胞体ストレス研究所 are jointly carrying out this project. In connection with the execution of the agreement, FRONTEO will invest in 小胞体ストレス研究所.
Head office: Tokushima, Tokushima Prefecture; Representative Director and President: Oyadomari Seiichi (親泊 政一). A biotechnology venture established in 2017 that works to commercialize research findings on endoplasmic reticulum stress responses and discover new drugs.
In this announcement the company addresses none of Contract Value / Offering price / Impact on Business Performance.
| Item | Details |
|---|---|
| Names of Products / Services Covered | ERS, a small-molecule drug candidate for diabetes treatment, Drug Discovery AI Factory（DDAIF）, DDAIF Innovation Bridge |
| Counterparty | 小胞体ストレス研究所株式会社 |
| Counterparty overview | Head office: Tokushima, Tokushima Prefecture; Representative Director and President: Oyadomari Seiichi (親泊 政一). A biotechnology venture established in 2017 that works to commercialize research findings on endoplasmic reticulum stress responses and discover new drugs. |
| Relationship with the Company | FRONTEO and 小胞体ストレス研究所 are jointly carrying out this project. In connection with the execution of the agreement, FRONTEO will invest in 小胞体ストレス研究所. |
| Contract Date | 7 October 2026 (mentioned as the date the agreement was signed) |
| Launch date | 7 October 2026 (project launch, actual) |
| Applicable area | Diabetes treatment drug development, Patient-stratification biomarker discovery, AI drug discovery, Diseases involving endoplasmic reticulum stress |
| Usage history | DDAIF has been adopted by multiple major pharmaceutical companies |
Items this document does not state (10)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The project aims to identify patient groups likely to respond to ERS, thereby improving the likelihood of demonstrating efficacy in clinical development, reducing the number of cases required, and improving the efficiency of patient selection and recruitment. It also aims to combine 小胞体ストレス研究所's research expertise with FRONTEO's AI analysis technology to develop new drug discovery approaches and accelerate ERS development.